Model List of Essential Medicines

Amidotrizoate

Section	Indications
Diagnostic agents > Radiocontrast media ◦ Parenteral > General injections > unspecified: 140 to 420 mg iodine per mL in 20 mL ampoule (as sodium or meglumine salt)	Amidotrizoate

Compound sodium lactate solution

Section	Indications
Solutions correcting water, electrolyte and acid-base disturbances > Parenteral ◦ Parenteral > General injections > IV: injectable solution	Hypovolaemic shock Other specified disorders of fluid, electrolyte or acid-base balance

Dalteparin

Section	Indications
Medicines affecting coagulation	Therapeutic equivalent to enoxaparin for Acute ischaemic heart disease Therapeutic equivalent to enoxaparin for Venous thromboembolism

Docusate sodium

Section	Indications
Medicines for other common symptoms in palliative care ◦ Oral > Liquid: 50 mg per 5 mL; 12.5 mg per 5 mL ◦ Oral > Solid > capsule: 100 mg	Palliative care

Enoxaparin

Section	Indications
Medicines affecting coagulation ◦ Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule	Acute ischaemic heart disease Venous thromboembolism

Glucose + sodium chloride

Section	Indications
Solutions correcting water, electrolyte and acid-base disturbances > Parenteral ◦ Parenteral > General injections > IV: 4% + 0.18% (equivalent to Na+ 30 mmol/L and Cl- 30 mmol/L; 5% + 0.9% (equivalent to Na+ 150 mmol/L and Cl- 150 mmol/L); 5% + 0.45% (equivalent to Na+ 75 mmol/L and Cl- 75 mmol/L)	Other specified disorders of fluid, electrolyte or acid-base balance

Heparin sodium

Section	Indications
Medicines affecting coagulation ◦ Parenteral > General injections > IV: 1000 IU per mL in 1 mL ampoule or vial; 20000 IU per mL in 1 mL ampoule or vial; 5000 IU per mL in 1 mL ampoule or vial	Acute ischaemic heart disease Unstable angina Venous thromboembolism

Levothyroxine

Section	Indications
Thyroid hormones and antithyroid medicines ◦ Oral > Solid: 50 µg (sodium salt); 100 µg (sodium salt); 25 µg (sodium salt)	Hypothyroidism

P-aminosalicylate sodium

Section	Indications
Antituberculosis medicines ◦ Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid) powder for oral solution	Multi-drug resistant Mycobacterium tuberculosis

Sodium calcium edetate

Section	Indications
Antidotes and other substances used in poisonings > Specific ◦ Parenteral > General injections > IV: 200 mg per mL in 5 mL ampoule	Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Sodium chloride

Section	Indications
Solutions correcting water, electrolyte and acid-base disturbances > Parenteral ◦ Parenteral > General injections > IV: 0.9% isotonic (equivalent to Na+ 154 mmol/L and Cl- 154 mmol/L)	Other specified disorders of fluid, electrolyte or acid-base balance

Sodium hyaluronate

Section	Indications
Ophthalmological preparations	Therapeutic equivalent to hypromellose for Keratoconjunctivitis sicca

Sodium hydrogen carbonate

Section	Indications
Solutions correcting water, electrolyte and acid-base disturbances > Parenteral ◦ Parenteral > General injections > IV: 1.4% isotonic (equivalent to Na+ 167 mmol/L and HCO3- 167 mmol/L); 8.4% in 10 mL ampoule (equivalent to Na+ 1000 mmol/L and HCO3- 1000 mmol/L)	Acidosis

Sodium nitrite

Section	Indications
Antidotes and other substances used in poisonings > Specific ◦ Parenteral > General injections > IV: 30 mg per mL in 10 mL ampoule	Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Sodium nitroprusside

Section	Indications
Antihypertensive medicines ◦ Parenteral > General injections > IV: 50 mg in ampoule powder for infusion	Hypertensive crisis

Sodium stibogluconate

Section	Indications
Antileishmaniasis medicines ◦ Parenteral > General injections > unspecified: 100 mg per mL in 30 mL vial	Visceral leishmaniasis Mucocutaneous leishmaniasis Cutaneous leishmaniasis

Sodium thiosulfate

Section	Indications
Antidotes and other substances used in poisonings > Specific ◦ Parenteral > General injections > IV: 250 mg per mL in 50 mL ampoule	Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
Dermatological medicines > Antifungal medicines ◦ Local > Topical > Solution: 15%	Pityriasis versicolor

Suramin sodium

Section	Indications
Medicines for the treatment of 1st stage African trypanosomiasis ◦ Parenteral > General injections > IV: 1 g in vial	Rhodesiense trypanosomiasis
Antifilarials ◦ Parenteral > General injections > IV: 1 g in vial	Filariasis

Thiopental

Section	Indications
General anaesthetics and oxygen > Injectable medicines	Therapeutic equivalent to propofol for Anaesthetics and therapeutic gases

Valproic acid (sodium valproate)

Section	Indications
Antiseizure medicines ◦ Oral > Liquid: 200 mg per 5 mL ◦ Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated); 100 mg tablet (crushable) ◦ Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 3 mL ampoule	Epilepsy or seizures Status epilepticus
Medicines for bipolar disorders ◦ Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated)	Bipolar or related disorders